Shots: The US FDA has accepted NDA and granted PR designation to Capmatinib as a 1L treatment for LA/m- MET exon 14 skipping (METex14) mutated NSCLC The NDA submission is […]readmore
Tags : Mutated
Shots: The P-III FLAURA study involves assessing of Tagrisso (80mg, qd) vs EGFR-TKIs (erlotinib, 50mg, qd /gefitinib, 250mg, qd) in 556 patients with LA/metastatic EGFRm NSCLC across 29 countries In […]readmore